<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Microbiol Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">J Microbiol Biotechnol</journal-id><journal-title-group><journal-title>Journal of Microbiology and Biotechnology</journal-title></journal-title-group><issn pub-type="ppub">1017-7825</issn><issn pub-type="epub">1738-8872</issn><publisher><publisher-name>The Korean Society for Microbiology and Biotechnology</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40374526</article-id><article-id pub-id-type="pmc">PMC12099628</article-id>
<article-id pub-id-type="doi">10.4014/jmb.2412.12014</article-id><article-id pub-id-type="publisher-id">jmb-35-e2412014</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject><subj-group><subject>Molecular and Cellular Microbiology (MCM)</subject><subj-group><subject>Antibiotics, Antifungals, and Antiviral compounds</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Main Ingredient of Yinhua Pinggan Granules Combined with Meropenem Alleviated Lung Injury Induced by Multidrug-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic> via Inhibiting NF-&#x003ba;B Pathway and NLRP3 Inflammasome Activation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Shengyao</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wan</surname><given-names>Haofang</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Guan</surname><given-names>Xiaodan</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Daojun</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Jiehong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wan</surname><given-names>Haitong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref><xref rid="cor2" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Biosafety Laboratory of Integrated Traditional Chinese and Western Medicine, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, <country>P. R. China</country></aff><aff id="aff2"><label>2</label>College of Traditional Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, <country>P. R. China</country></aff><aff id="aff3"><label>3</label>Fuyang Research Institute of Zhejiang Chinese Medical University, Hangzhou 311400, <country>P.R. China</country></aff><aff id="aff4"><label>4</label>Hangzhou First People&#x02019;s Hospital, Hangzhou 310003, <country>P.R. China</country></aff><aff id="aff5"><label>5</label>Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan Province, <country>P. R. China</country></aff><author-notes><corresp id="cor1">
<label>*</label>Corresponding authors J Yang E-mail: <email xlink:href="yjhong@zcmu.edu.cn">yjhong@zcmu.edu.cn</email></corresp><corresp id="cor2">
H Wan E-mail: <email xlink:href="whtong@126.com">whtong@126.com</email>
</corresp><fn id="fn1" fn-type="equal"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>35</volume><elocation-id>e2412014</elocation-id><history><date date-type="received"><day>9</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>20</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 by the authors. Licensee KMB</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is an open access article distributed under the terms and conditions of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution (CC BY) license</ext-link></license-p></license></permissions><abstract><p>In combating the global epidemic of multidrug-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> (MDR-KP), combination therapy with the active ingredient of meropenem (MER) is gaining attention as a new therapeutic approach. In this study, the effect of OAY (orthogonal combination drug of active ingredients in YHPG) in combination with MER on MDR-KP was assessed using the microdilution technique. Additionally, the antimicrobial effect of OAY in combination with MER on MDR-KP was analyzed by reactive oxygen species (ROS), alkaline phosphatase (AKP), and RT-qPCR techniques. Furthermore, the expression levels of critical targets within the NF-&#x003ba;B/NLRP3 pathway were assessed via HE staining and western blot in an MDR-KP-infected mice model. Our results confirmed that the OAY-MER combinations inhibited MDR-KP biofilm formation. In the meantime, the compromise of membrane integrity led to the generation of ROS, which subsequently resulted in a decrease in the activity of intracellular enzymes, specifically AKP. We also found that the combination of OAY-MER reversed tmexCD1-toprJ-mediated MER resistance in MDR-KP. Finally, by a mouse model of MDR-KP infection, the data demonstrated that OAY and YHPG ameliorated lung injury and bacterial infections in the lungs, and significantly reduced NF-&#x003ba;B P-p65, NLRP3, and C-GSDMD protein expression in mouse lung tissues. The findings suggest that the combination of OAY with meropenem may have great potential for clinical application and could provide a theoretical basis for its use in treating MDR-KP infections.</p></abstract><kwd-group><kwd>Multidrug-resistant <italic toggle="yes">Klebsiella pneumoniae</italic></kwd><kwd>Yinhua Pinggan granules</kwd><kwd>combination therapy</kwd><kwd>tmexCD1-toprJ</kwd><kwd>reactive oxygen species</kwd><kwd>NF-&#x003ba;B</kwd><kwd>NLRP3</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p><italic toggle="yes">Klebsiella pneumoniae</italic> (KP) possesses an extensive accessory genome that contributes to its ability to cause various infections [<xref rid="ref1" ref-type="bibr">1</xref>]. Due to its extended antibiotic resistance and global spread via mobile genetic elements, multidrug-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> (MDR-KP) has become an imminent threat in the clinical setting, leading to higher mortality [<xref rid="ref2" ref-type="bibr">2</xref>, <xref rid="ref3" ref-type="bibr">3</xref>]. Meropenem (MER), a beta-lactam antibiotic, is used to treat a variety of infections, including sepsis and meningitis [<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>]. Moreover, clinical treatment has become increasingly difficult for drug-resistant and hypervirulent strains of bacteria, hence the urgent need to find new strategies for MDR-KP.</p><p>Numerous signaling pathways contribute to the inflammatory response, with NF-&#x003ba;B recognized as an important component [<xref rid="ref6" ref-type="bibr">6</xref>]. Activated NF-&#x003ba;B plays a significant role in modulating cell proliferation and apoptosis, as well as in the synthesis of inflammatory cytokines [<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr"/>-<xref rid="ref8" ref-type="bibr">8</xref>]. In addition, research has indicated the activated NF-&#x003ba;B may be an upstream regulator in inflammasome [<xref rid="ref6" ref-type="bibr">6</xref>]. Inflammasomes are crucial components in the innate immune system, with NLRP3 inflammasome (which is comprised of NLRP3, ASC, and caspase-1), being the most extensively studied [<xref rid="ref9" ref-type="bibr">9</xref>]. GSDMD undergoes cleavage by inflammatory caspases and demonstrates pore-forming capabilities that facilitate the process of pyroptosis [<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref11" ref-type="bibr">11</xref>]. Another study showed that dynasore greatly inhibited the NF-&#x003ba;B signaling pathway, activated the NLRP3 inflammasome, leading to mitigated LPS-induced acute lung injury in a mice model [<xref rid="ref12" ref-type="bibr">12</xref>]. Therefore, the NF-&#x003ba;B/NLRP3 pathway probably represents a novel therapeutic target for bacterial infections and lung injury.</p><p>The mechanisms of bacterial resistance to MER agents include drug efflux and the loss of porins, which are significant factors contributing to this resistance [<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>]. TmexCD1-<italic toggle="yes">toprJ1</italic> was recently reported to confer clinical strains significant resistance and weaken the effectiveness of tigecycline (TIG) [<xref rid="ref15" ref-type="bibr">15</xref>, <xref rid="ref16" ref-type="bibr">16</xref>]. The tmexCD-toprJ gene cluster underwent horizontal gene transfer between bacteria via plasmids, a mechanism that enabled the rapid spread of drug-resistant genes in bacterial populations [<xref rid="ref17" ref-type="bibr">17</xref>]. However, it is not known whether the tmexCD1-<italic toggle="yes">toprJ1</italic> efflux pump mediates the efflux action of clinically important pathogens on MER. In addition, research had shown the generation of reactive oxygen species (ROS) contributed to the bacteriostatic effects of antibiotics [<xref rid="ref18" ref-type="bibr">18</xref>]. An overabundance of ROS can induce lipid peroxidation, which diminishes the fluidity of the bacterial membrane and alters its properties. This alteration subsequently compromises the integrity of membrane proteins, ultimately resulting in bacterial cell death [<xref rid="ref19" ref-type="bibr">19</xref>, <xref rid="ref20" ref-type="bibr">20</xref>]. Furthermore, research indicates that nearly all strains of KP are capable of biofilm formation, particularly those exhibiting elevated resistance rates [<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr"/>-<xref rid="ref23" ref-type="bibr">23</xref>]. Biofilm formation, one of the most important virulence features of KP, activates virulence factors and resists phagocytosis, thus facilitating the onset and development of bacterial infectivity and resistance [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>]. Moreover, biofilm formation significantly enhances the expression of efflux pumps compared to planktonic bacteria, resulting in heightened bacterial resistance to antibiotics [<xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr"/>-<xref rid="ref27" ref-type="bibr">27</xref>].</p><p>Antimicrobial drug development has always been a challenge, as evidenced by the limited number of new antibiotics that have been successfully introduced into clinical practice [<xref rid="ref28" ref-type="bibr">28</xref>, <xref rid="ref29" ref-type="bibr">29</xref>]. Consequently, the introduction of viable methods to expand treatment options is urgently required. Repurposing approved drugs as antibiotic adjuvants could well improve the effects of currently available antibiotics. Yinhua Pinggan granules (YHPG) are a traditional Chinese medicine that contains ingredients such as honeysuckle, tiger balm, <italic toggle="yes">Pueraria lobata</italic> (kudzu), and bitter amygdalin (Amy). We found that YHPG and its active ingredients, which include chlorogenic acid (CA), puerarin (Pue), Amy and polydatin (PD), restored the inhibitory activity against the MDR bacteria by facilitating the antibiotic's intra-bacterial accumulation [<xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr"/><xref rid="ref32" ref-type="bibr"/><xref rid="ref33" ref-type="bibr"/>-<xref rid="ref34" ref-type="bibr">34</xref>]. In this research, the four main components were selected for orthogonal experiments, and we referred to our previous studies for the maximum harmless concentrations to the cells [<xref rid="ref31" ref-type="bibr">31</xref>, <xref rid="ref33" ref-type="bibr">33</xref>, <xref rid="ref35" ref-type="bibr">35</xref>].</p><p>Consequently, we aimed in this study to find a promising therapeutic strategy for MDR-KP, and to elucidate MER in combination with the active ingredients of OAY/YHPG, as well as the mechanism by which the OAY/YHPG-MER combination acted against MDR-KP.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Reagents</title><p>CA, Pue, Amy, and PD were bought from the Chengdu Alfa Biotechnology (China). Crystal violet staining solutions were purchased from Beyotime (China). Alkaline phosphatase (AKP) kits were obtained from Beyotime. The 2X Universal SYBR Green Fast qPCR Mix was purchased from ABclonal (China), and ROS kits (Green Fluorescent) were bought from Biobying (China).</p></sec><sec><title>Bacterial Strains and Culture Conditions</title><p>The MDR-KP strains were collected from Hangzhou First People&#x02019;s Hospital, China. After the identification of genome sequencing (Personal Biotechnology Co., Ltd., China), MDR-KP was cultured in LB at 200 rpm and 37&#x000b0;C, and then measured at OD<sub>600</sub> in a microplate reader (Tecan, Switzerland).</p></sec><sec><title>MIC Determination</title><p>The MIC of antimicrobial drugs, such as cefotaxime sodium (CTX), MER, and TIG was measured by methods developed by the Clinical Laboratory Standardization Institute (CLSI). MDR-KP was incubated overnight in LB at 200 rpm. The diluted bacterial suspension and drug were added to a 96-well plate, incubated at 37&#x000b0;C for 18 h, and then measured at OD<sub>600</sub> in a microplate reader.</p></sec><sec><title>Quadrature Experiment</title><p>The quadrature experiment was designed based on the MIC of the four YHPG active ingredients (CA, Pue, Amy, and PD) set at high, medium, and low concentrations. Where the concentration of CA was 4, 8, and 16 &#x003bc;g/ml, the concentration of Pue was 32, 64, and 128 &#x003bc;g/ml; the concentration of Amy was 59.25, 118.5, and 237 &#x003bc;g/ml, and the concentration of PD was 15.5, 31, and 62 &#x003bc;g/ml. Orthogonal combinations of YHPG active ingredients are listed in <xref rid="T1" ref-type="table">Table 1</xref>.</p></sec><sec><title>Killing Studies</title><p>Generally, MDR-KP was incubated overnight in LB at 200 rpm. Bacteria were then treated with different antimicrobial drug combinations or MER or their combinations and were cultured at 37&#x000b0;C and 200 rpm. The bacterial OD<sub>600</sub> measurements were done using a microplate reader.</p></sec><sec><title>Detection of Live and Dead Bacteria by Flow Cytometry</title><p>In brief, MDR-KP was diluted with PBS into LB broth containing different antimicrobial drugs or MER or their combinations at 37&#x000b0;C and 200 rpm. After treatment, bacteria were collected, washed, and dissolved in 1&#x000d7; binding buffer. Bacteria were harvested and subjected to staining with an Annexin-V/FITC and PI staining kit for 15 min in a dark environment, followed by analysis via flow cytometry. Analysis of the result was carried out using FlowJo 10.</p></sec><sec><title>Antibiofilm Activity Assay</title><p>MDR-KP was diluted with PBS into LB broth containing different antimicrobial drugs or MER or their combinations at 37&#x000b0;C and 200 rpm overnight. After treatment, to quantify biofilm density, the biofilms were washed to remove free-floating planktonic bacteria, using 10% paraformaldehyde. Biofilms developed by adherent microorganisms on the plate were subjected to staining with crystal violet, and their absorbance was measured at 595 nm.</p></sec><sec><title>Determination of AKP Activity</title><p>MDR-KP was diluted with PBS into LB broth containing different antimicrobial drugs or MER or their combinations at 37&#x000b0;C and 200 rpm overnight. After treatment, using the AKP kit, extracellular AKP activity at 400 nm-415 nm was detected via the microplate reader.</p></sec><sec><title>qRT-PCR</title><p>MDR-KP was diluted into LB broth containing different antimicrobial drugs or MER or their combinations at 37&#x000b0;C and 200 rpm. After 18 h, MDR-KP was collected, the total RNA was extracted using a kit, and the total RNA purity was also measured. Quantification of mRNA was conducted by using 2X Universal SYBR Green Fast qPCR Mix. Primer sequences are listed in <xref rid="T2" ref-type="table">Table 2</xref>.</p></sec><sec><title>ROS Measurement</title><p>The ROS activity of MDR-KP was assessed via quantifying the fluorescence intensity of the fluorescent probe DCFH-DA via flow cytometry. Briefly, MDR-KP was collected and the samples were incubated with a DCFH-DA probe at a dilution of 1:1000 in PBS for 30 min. Following incubation, samples were washed with PBS to remove any unbound probes. Ultimately, flow cytometry was used to indicate the levels of intracellular ROS.</p></sec><sec><title>Carba NP Detection Test</title><p>Following preparation, 150 &#x003bc;l of NP solution (pH 7.8 &#x000b1; 0.2) was added to four groups of 1.5 ml sterile centrifuge tubes (Liquid A, Liquid A with drug, Liquid B, and Liquid B with drug) into 96-well plates to treat different groups. Then, 50 &#x003bc;l of 1&#x000d7;10<sup>8</sup> CFUs/ml of bacterial concentration was added, mixed, and incubated for 5-6 h. The results were recorded by observing the color change with the naked eye and by measuring the absorbance value of the mixtures at OD<sub>492</sub>.</p></sec><sec><title>Animal Experiments</title><p>Animals and group-housed, clean-grade BALB mice (male, 20 &#x000b1; 2 g) were approved by the Experimental Animal Center of Zhejiang University of Chinese Medicine and experiments were conducted in the Second-Level Biosafety Laboratory (P2) of Hangzhou First People&#x02019;s Hospital affiliated with Zhejiang University. Mice were randomized into a control group, a model group, an OAY (CA, Pue, Amy, PD) group, and a YHPG 18 g/kg group. After intraperitoneal injection of 4% chloral hydrate anesthesia, the model group and drug treatment group were established via intranasal instillation of 50 &#x003bc;l MDR-KP (concentration of 10<sup>9</sup> CFU/ml), with PBS as a control group. Mice in the OAY group were injected subcutaneously with the drug 2 h after infection (the YHPG group was administered by gavage), once, and again 12 h later, and then euthanized 24 h later. During this period, the mice were fed normally. In addition, the animal experiments were protected in accordance with the relevant regulations of the Animal Medical Center of Zhejiang University and approved by the Ethics Committee (No. 29391).</p></sec><sec><title>Specimen Collection</title><p>Blood collection: mice were anesthetized with 4% chloral hydrate, the area around the eyeballs of live mice was disinfected, and the blood was collected. Lung sampling: at 12 h after the last administration, the neck was removed and lung tissue was collected for testing pathological, biological, and other indicators. Subsequently, the lung tissues were homogenized and dissolved in an extraction buffer to facilitate the analysis of malondialdehyde (MDA) and superoxide dismutase (SOD) levels utilizing designated assay kits. The concentrations of the inflammatory cytokine interleukin-1 beta (IL-1&#x003b2;) were then quantified by ELISA kits. The homogenate underwent centrifugation at 2,500 &#x000d7;<italic toggle="yes">g</italic> for 10 min, after which the supernatant was collected. Counts of MDR-KP organisms were determined by plating serial dilutions of the lung homogenates on LB agar overnight.</p></sec><sec><title>Wet-to-Dry Lung Weight Ratio</title><p>Fluid content in the lungs was measured by carefully cutting the right lung, separating the upper right lung, and then measuring its wet weight. Then, the right upper lung tissue was dried at 60&#x000b0;C for 24 h to measure its dry weight.</p></sec><sec><title>Hematoxylin &#x00026; Eosin (HE) Staining</title><p>The right middle lung tissues from different groups of mice were collected, rinsed with physiological saline, and fixed in 4% paraformaldehyde solution for 48 h. Then, the tissues were dehydrated with ethanol, embedded in paraffin, sectioned, stained with HE, and finally observed by CaseViewer software.</p></sec><sec><title>Immunohistochemistry Staining</title><p>In summary, following the processes of deparaffinization and rehydration, lung tissue sections were subjected to immersion in a 1&#x000d7; sodium citrate buffer at 98&#x000b0;C for 15 min to facilitate antigen retrieval, and then treated with 3% hydrogen peroxide. Subsequently, the sections were treated with goat serum and then incubated overnight at 4&#x000b0;C with primary antibody against cleaved caspase-1. The sections were then incubated with secondary antibodies for 30 min. Ultimately, all sections were stained with DAB reagent and counterstained with hematoxylin. Observations of the sections were conducted utilizing an optical microscope.</p></sec><sec><title>Western Blot</title><p>Lung tissues from the left side of each group of mice were collected and homogenized. Following extraction of total protein from lung tissue samples, the total protein samples were denatured and separated by SDS-PAGE, and then transferred to a PVDF membrane. The membrane was blocked with 5% BSA for 60 min. Subsequent to the washing procedure, the membrane was incubated with appropriate primary antibodies: C-GSDMD (1:1000), NLRP3 (1:1000), and NF-&#x003ba;B P-p65 (1:1000). After being left overnight, the secondary antibody was diluted and incubated at room temperature. Bands were exposed and visualized using enhanced chemiluminescence (ECL), and band density was quantified using Image J software.</p></sec><sec><title>Statistical Analysis</title><p>All experimental results were analyzed via GraphPad. One-way analysis of variance (ANOVA) was utilized to determine any significant differences. <italic toggle="yes">p</italic> &#x0003c; 0.05 and <italic toggle="yes">p</italic> &#x0003c; 0.01 were considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Microbiological Characteristics of MDR-KP Clinical Isolates</title><p>MDR-KP strains were resistant to MER (256 &#x003bc;g/ml) and CTX (2,048 &#x003bc;g/ml) but were sensitive to TIG (2 &#x003bc;g/ml)(<xref rid="F1" ref-type="fig">Fig. 1F</xref>-<xref rid="F1" ref-type="fig">1H</xref>). We next used the lowest harmless concentration of the CA (<xref rid="F1" ref-type="fig">Fig. 1A</xref>), Pue (<xref rid="F1" ref-type="fig">Fig. 1B</xref>), Amy (<xref rid="F1" ref-type="fig">Fig. 1C</xref>), and PD (<xref rid="F1" ref-type="fig">Fig. 1D</xref>) in our experiments. The growth rate of MDR-KP was not significantly decreased with CA, Pue, Amy, and PD (<xref rid="F1" ref-type="fig">Fig. 1E</xref>).</p></sec><sec><title>Antimicrobial Effects of OAY in Combination with MER on MDR-KP</title><p>There was a significant difference when OAY was combined with MER compared to the control (<xref rid="F2" ref-type="fig">Fig. 2A</xref> and <xref rid="F2" ref-type="fig">2B</xref>). By matching Annexin-V to PI, it was possible to distinguish between live and apoptotic-like, dead bacteria. As shown in <xref rid="F2" ref-type="fig">Fig. 2D</xref> and <xref rid="F2" ref-type="fig">2E</xref>, apoptosis-like condition increased and survival decreased with MER in combination with OAY groups. Taken together, OAY could compromise bacterial structure and lead to an apoptosis-like appearance of MDR-KP.</p></sec><sec><title>The OAY/YHPG-MER Combination Showed Synergistic Activity against tmexCD1-<italic toggle="yes">toprJ1</italic>-Carrying Bacteria and Promoted ROS</title><p>Having demonstrated that OAY enhanced the bactericidal effect of MER, we sought to understand the underlying mechanisms. First, we determined the gene expression in efflux pump tmexCD1-<italic toggle="yes">toprJ1</italic> by qPCR. As shown in <xref rid="F3" ref-type="fig">Fig. 3A</xref>, compared with MER group, the expression of <italic toggle="yes">tmexC1</italic>, <italic toggle="yes">tmexD1</italic>, and <italic toggle="yes">toprJ1</italic> was significantly inhibited by MER combined with OAY/YHPG. As shown in <xref rid="F3" ref-type="fig">Fig. 3B</xref>, the intensity of OAY/YHPG-MER combinations-induced intracellular fluorescence of the bacteria was enhanced. These results suggested that OAY/YHPG-MER combinations could block the RND efflux pump and promote oxidative stress, resulting in the intracellular bacteria accumulation of MER.</p></sec><sec><title>OAY/YHPG-MER Damaged the Bacterial Membrane of MDR-KP</title><p>The elevated expression of ROS resulting from the OAY/YHPG-MER combination subsequently enhanced the permeability of the bacterial membrane, ultimately causing bacterial death. To confirm this, we analyzed the OAY/YHPG-MER combination influence in MDR-KP biofilm formation capacity by crystal violet staining assay. As shown in <xref rid="F4" ref-type="fig">Fig. 4B</xref>, following staining with crystalline violet, a clear color gradient was observed. The AKP activity in the untreated control group showed no significant change within each time point. Meanwhile, the AKP activity in the treated group showed a time-dependent increase, and particularly, the highest activity was observed in the OAY/YHPG group in combination with MER. As shown in <xref rid="F4" ref-type="fig">Fig. 4D</xref> and <xref rid="F4" ref-type="fig">4E</xref>, by analyzing the color change (<xref rid="F4" ref-type="fig">Fig. 4D</xref>) and the absorbance value of the samples out of 492 nm (<xref rid="F4" ref-type="fig">Fig. 4E</xref>), we found that the color turned to red in the wells of the OAY-MER combination co-culture, and the OD<sub>492</sub> nm value of the combined group changed significantly, which suggested that OAY in combination with MER inhibited carbapenemase production by MDR-KP. This result showed that the OAY/YHPG -MER combination via inducing ROS production caused destruction of the permeability of bacterial wall, ultimately contributing to bacterial death.</p></sec><sec><title>OAY (Com.7) and YHPG Ameliorated MDR-KP-Induced Lung Injury in Mice</title><p>Briefly, we found the bacterial inhibition effect of Com.7 was superior to that of Com.1, and therefore we used Com.7 for subsequent in vivo animal experiments. To investigate the impact of OAY (Com.7) on lung injury induced by MDR-KP, we performed HE analysis and evaluated lung W/D in mice lung tissues. In comparison to the control group, the MDR-KP infection led to significant lung injury. Conversely, treatment with OAY and YHPG markedly ameliorated the lung injury induced by MDR-KP, as evidenced by a reduction in both intra-alveolar and interstitial edema (<xref rid="F5" ref-type="fig">Fig. 5A</xref>). The W/D mass ratio was significantly higher in the model group, suggesting that MDR-KP infection induced pulmonary edema in mice. In contrast, drug treatment improved MDR-KP-induced pulmonary edema. We therefore concluded that OAY and YHPG could therapeutically attenuate pulmonary edema induced by MDR-KP in mice (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). We also assessed lung infections in mice by examining lung tissue for levels of bacteria. As illustrated in <xref rid="F5" ref-type="fig">Fig. 5C</xref>, the concentration of MDR-KP was significantly elevated in the model group, and by contrast, the groups that received pretreatment with YHPG and OAY exhibited a diminished MDR-KP content in the lung tissue. The bacterial load was greatly declined in the YHPG+MER and OAY+MER treatment groups compared to the MER group. These findings indicated that YHPG and OAY exerted considerable effects in reducing the levels of MDR-KP in the lung. As shown in <xref rid="F5" ref-type="fig">Fig. 5D</xref> and <xref rid="F5" ref-type="fig">5E</xref>, MDR-KP significantly elevated MDA levels and reduced SOD levels compared to the control group, while YHPG and OAY treatment reversed this effect.</p></sec><sec><title>OAY (Com.7) and YHPG Inhibited the Activation of Pyroptosis via the NF&#x02010;&#x003ba;B/NLRP3 Pathway in MDR-KP-Infected Mice</title><p>MDR-KP mice exhibited a much higher protein level of caspase-1, compared with control mice, while YHPG and OAY treatment reversed this effect (<xref rid="F6" ref-type="fig">Fig. 6A</xref>). The levels of IL-1&#x003b2; were markedly elevated following MDR-KP infection in comparison to the control group, while YHPG and OAY treatment reversed this effect (<xref rid="F6" ref-type="fig">Fig. 6B</xref>). Then, we assessed the expression level of pivotal proteins of the inflammatory pathway (NF&#x02010;&#x003ba;B/NLRP3, GSDMD). Results demonstrated that MDR-KP infection significantly elevated the expression of NF&#x02010;&#x003ba;B, NLRP3, and GSDMD. OAY and YHPG groups both successfully inhibited the activation of NLRP3 and P-p65 induced by MDR-KP infection. The above data suggested that OAY and YHPG mainly attenuate MDR-KP-induced lung injury via suppression of the NF&#x02010;&#x003ba;B/NLRP3 pathway.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Antimicrobial resistance represents a significant challenge to global health and seriously jeopardizes patient lives [<xref rid="ref36" ref-type="bibr">36</xref>]. The integration of antibiotics with non-antibiotic agents that may either impede bacterial resistance mechanisms or augment the efficacy of antibiotics presents a viable and sustainable approach to addressing the challenge posed by multidrug-resistant bacteria [<xref rid="ref36" ref-type="bibr">36</xref>]. We observed that the combination of OAY/YHPG-MER effectively counteracted the MER resistance mediated by tmexCD-toprJ, thereby underscoring the efficacy of this drug combination with our research. The efflux pump tmexCD-toprJ gene cluster underwent horizontal gene transfer between bacteria via plasmids, a mechanism that enabled the rapid spread of drug-resistant genes in bacterial populations, allowing bacteria to exhibit multi-drug resistance to quinolones, fluoroquinolones, aminoglycosides, and tetracycline antibiotics [<xref rid="ref17" ref-type="bibr">17</xref>]. Previous studies have shown that BEN, a non-steroidal anti-inflammatory drug, reversed tmexCD-toprJ-mediated TIG resistance and significantly enhanced TIG antimicrobial activity against drug-resistant KP and <italic toggle="yes">P. mirabilis</italic> [<xref rid="ref37" ref-type="bibr">37</xref>]. In this study, the expression of <italic toggle="yes">tmexC1</italic>, <italic toggle="yes">tmexD1</italic>, and <italic toggle="yes">toprJ1</italic> in MDR-KP was significantly inhibited by MER combined with OAY/YHPG. Consequently, the combination of antibiotics with non-antibiotic agents presents a novel strategy to deal with the bacterial resistance situation.</p><p>Oxidative stress induced by ROS, a novel antibacterial strategy, has the potential to inflict damage on nucleic acids, proteins, and lipids, disrupt the bacterial oxidative milieu, and ultimately lead to bacterial death [<xref rid="ref18" ref-type="bibr">18</xref>, <xref rid="ref38" ref-type="bibr">38</xref><xref rid="ref39" ref-type="bibr"/>-<xref rid="ref40" ref-type="bibr">40</xref>]. ROS production contributed to the bacteriostatic effects of antibiotics [<xref rid="ref18" ref-type="bibr">18</xref>]. In our research, the findings indicated that OAY also promoted the accumulation of ROS. In addition, the OAY/YHPG-MER combination inhibited biofilm formation, which subsequently promoted an increased uptake of MER, thereby augmenting the killing of MDR-KP bacteria. AKP was often used to reflect the integrity of the bacterial outer membrane and cell wall [<xref rid="ref41" ref-type="bibr">41</xref><xref rid="ref42" ref-type="bibr"/>-<xref rid="ref43" ref-type="bibr">43</xref>]. It had been reported that the outer membrane of <italic toggle="yes">E. coli</italic>, which dealt with oregano essential oil, was disrupted and extracellular AKP activity increased [<xref rid="ref43" ref-type="bibr">43</xref>]. This result was similar to our findings; the higher AKP activity of bacteria was increased with the combination of OAY/YHPG-MER, which indicated that the MDR-KP outer membrane had been damaged. Overall, the combination of OAY/YHPG-MER induced oxidative stress in bacteria, disrupting the integrity of the outer membrane and cell wall. Meanwhile, the increased permeability of the outer membrane led to MER accumulation, and ultimately to bacterial death. In conclusion, combination therapy using OAY/YHPG-MER has enormous potential to restore antibiotic efficacy in the clinical setting.</p><p>Numerous signaling pathways contribute to the inflammatory response, and NF-&#x003ba;B is recognized as a critical component [<xref rid="ref44" ref-type="bibr">44</xref>]. Activated NF&#x02010;&#x003ba;B plays a significant role in modulating cell proliferation and apoptosis, as well as in the synthesis of inflammatory cytokines [<xref rid="ref7" ref-type="bibr">7</xref>, <xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref44" ref-type="bibr">44</xref>]. LPS was known to activate the TLR4/NF-&#x003ba;B signaling pathway and initiate transcription of its downstream inflammatory cytokines IL-6, TNFa, and chemokines [<xref rid="ref45" ref-type="bibr">45</xref>, <xref rid="ref46" ref-type="bibr">46</xref>]. In this research, our results indicated that MDR-KP markedly increased the expression levels of NF-&#x003ba;B, while OAY and YHPG decreased the expression of NF-&#x003ba;B in MDR-KP-infected mice. NLRP3 inflammasome, one of the most essential steps in host defense, is activated by NF-&#x003ba;B, thereby upregulating downstream target proteins caspase-1, pro-IL-18, as well as pro-IL-18 expression [<xref rid="ref46" ref-type="bibr">46</xref>, <xref rid="ref47" ref-type="bibr">47</xref>]. In this research, lung tissues from mice subjected to exposure to MDR-KP exhibited elevated NLRP3 and caspase-1 as well as cleaved GSDMD expression, while YHPG and OAY treatment reversed this effect. In conclusion, the therapeutic potential of OAY in addressing pyroptosis in lung injury may be related to the activation of the NLRP3 inflammasome.</p><p>Our study showed the combination of OAY/YHPG-MER as a promising antimicrobial extract that potentially increases the susceptibility of resistant strains to antibiotics. As shown in <xref rid="F7" ref-type="fig">Fig. 7</xref>, we also propose that the OAY/YHPG-MER combination disrupts the overall integrity of the bacterial membrane through tmexCD-toprJ and oxidative stress, leading to enhanced cell wall permeability and thereby contributing to the accumulation of antimicrobial drugs in bacteria, ultimately leading to bacterial death. Furthermore, OAY could ameliorate the pathological process of lung injury due to MDR-KP infection, which might be by inhibiting the NF-&#x003ba;B pathway and activating NLRP3 inflammasome. In conclusion, a combination of OAY/YHPG-MER demonstrated significant potential for enhancing the effectiveness of antibiotics within clinical applications and our study provides a platform for future research.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>In conclusion, these data suggested that a combination of OAY/YHPG-MER was a promising treatment method for addressing the resistance conferred by novel RND efflux pumps to MER. However, there were still several limitations in this study. First, no tmexCD-toprJ pump inhibition experiments were done, and the effect of the drug on the upstream genes of tmexCD-toprJ was not clarified. Second, specific targets regarding NF-&#x003ba;B/NLRP3 signaling pathways were not studied in depth. Finally, the specific mechanism of the drug has not been elucidated, and additional preclinical studies are necessary to thoroughly investigate the therapeutic potential of this drug combination.</p></sec></body><back><ack><title>Acknowledgments</title><p>Funding for this study was provided by the National Natural Science Foundation of China/Key Project (81930111), and the Biosafety Laboratory of Integrated Traditional Chinese and Western Medicine, Zhejiang Chinese Medical University.</p></ack><fn-group><fn fn-type="COI-statement"><p>
<bold>Conflicts of Interest</bold>
</p><p>The authors have no financial conflicts of interest to declare.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>RM</given-names></name>
<name><surname>Bachman</surname><given-names>MA</given-names></name>
</person-group><year>2018</year><article-title>Colonization, infection, and the accessory genome of <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>Front. Cell. Infect. Microbiol.</source><volume>8</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2018.00004</pub-id><!--<pub-id pub-id-type="pmcid">PMC5786545</pub-id>--><pub-id pub-id-type="pmid">29404282</pub-id>
</element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lan</surname><given-names>P</given-names></name>
<name><surname>Jiang</surname><given-names>Y</given-names></name>
<name><surname>Zhou</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>Y</given-names></name>
</person-group><year>2021</year><article-title>A global perspective on the convergence of hypervirulence and carbapenem resistance in <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>J. Glob. Antimicrob. Resist.</source><volume>25</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2021.02.020</pub-id><pub-id pub-id-type="pmid">33667703</pub-id>
</element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aksomaitiene</surname><given-names>J</given-names></name>
<name><surname>Novoslavskij</surname><given-names>A</given-names></name>
<name><surname>Kudirkiene</surname><given-names>E</given-names></name>
<name><surname>Gabinaitiene</surname><given-names>A</given-names></name>
<name><surname>Malakauskas</surname><given-names>M</given-names></name>
</person-group><year>2020</year><article-title>Whole genome sequence-based prediction of resistance determinants in high-level multidrug-resistant <italic toggle="yes">Campylobacter jejuni</italic> isolates in Lithuania</article-title><source>Microorganisms</source><volume>9</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.3390/microorganisms9010066</pub-id><!--<pub-id pub-id-type="pmcid">PMC7823968</pub-id>--><pub-id pub-id-type="pmid">33383765</pub-id>
</element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raza</surname><given-names>A</given-names></name>
<name><surname>Ngieng</surname><given-names>SC</given-names></name>
<name><surname>Sime</surname><given-names>FB</given-names></name>
<name><surname>Cabot</surname><given-names>PJ</given-names></name>
<name><surname>Roberts</surname><given-names>JA</given-names></name>
<name><surname>Popat</surname><given-names>A</given-names></name>
<etal/>
</person-group><year>2021</year><article-title>Oral meropenem for superbugs: challenges and opportunities</article-title><source>Drug Discov. Today</source><volume>26</volume><fpage>551</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.11.004</pub-id><pub-id pub-id-type="pmid">33197621</pub-id>
</element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slama</surname><given-names>TG</given-names></name>
</person-group><year>2008</year><article-title>Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use</article-title><source>Crit. Care</source><volume>12</volume><fpage>233</fpage><pub-id pub-id-type="doi">10.1186/cc6994</pub-id><!--<pub-id pub-id-type="pmcid">PMC2592734</pub-id>--><pub-id pub-id-type="pmid">18983709</pub-id>
</element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q</given-names></name>
<name><surname>Ma</surname><given-names>H</given-names></name>
<name><surname>Sun</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>B</given-names></name>
<name><surname>Xiao</surname><given-names>Y</given-names></name>
<name><surname>Pan</surname><given-names>S</given-names></name>
<etal/>
</person-group><year>2019</year><article-title>The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia</article-title><source>J. Exper. Clin. Cancer Res</source><volume>38</volume><fpage>199</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1365-y</pub-id><!--<pub-id pub-id-type="pmcid">PMC6696673</pub-id>--><pub-id pub-id-type="pmid">31096997</pub-id>
</element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruland</surname><given-names>J</given-names></name>
</person-group><year>2011</year><article-title>Return to homeostasis: downregulation of NF-&#x003ba;B responses</article-title><source>Nat. Immunol.</source><volume>12</volume><fpage>709</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1038/ni.2055</pub-id><pub-id pub-id-type="pmid">21772279</pub-id>
</element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai</surname><given-names>JL</given-names></name>
<name><surname>Liu</surname><given-names>YH</given-names></name>
<name><surname>Liu</surname><given-names>C</given-names></name>
<name><surname>Qi</surname><given-names>MP</given-names></name>
<name><surname>Liu</surname><given-names>RN</given-names></name>
<name><surname>Zhu</surname><given-names>XF</given-names></name>
<etal/>
</person-group><year>2017</year><article-title>Indirubin inhibits LPS-induced inflammation <italic toggle="yes">via</italic> TLR4 abrogation mediated by the NF-kB and MAPK signaling pathways</article-title><source>Inflammation</source><volume>40</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s10753-016-0447-7</pub-id><pub-id pub-id-type="pmid">27718095</pub-id>
</element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>M</given-names></name>
<name><surname>Geng</surname><given-names>N</given-names></name>
<name><surname>Du</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>Z</given-names></name>
<name><surname>Gao</surname><given-names>X</given-names></name>
<etal/>
</person-group><year>2022</year><article-title><italic toggle="yes">Staphylococcus aureus</italic> mediates pyroptosis in bovine mammary epithelial cell via activation of NLRP3 inflammasome</article-title><source>Vet. Res.</source><volume>53</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s13567-022-01027-y</pub-id><!--<pub-id pub-id-type="pmcid">PMC8817610</pub-id>--><pub-id pub-id-type="pmid">35123552</pub-id>
</element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>J</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>K</given-names></name>
<name><surname>Shi</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>H</given-names></name>
<etal/>
</person-group><year>2015</year><article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title><source>Nature</source><volume>526</volume><fpage>660</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nature15514</pub-id><pub-id pub-id-type="pmid">26375003</pub-id>
</element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kesavardhana</surname><given-names>S</given-names></name>
<name><surname>Malireddi</surname><given-names>RKS</given-names></name>
<name><surname>Kanneganti</surname><given-names>TD</given-names></name>
</person-group><year>2020</year><article-title>Caspases in cell death, inflammation, and pyroptosis</article-title><source>Ann. Rev. Immunol.</source><volume>38</volume><fpage>567</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-073119-095439</pub-id><!--<pub-id pub-id-type="pmcid">PMC7190443</pub-id>--><pub-id pub-id-type="pmid">32017655</pub-id>
</element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shan</surname><given-names>M</given-names></name>
<name><surname>Wan</surname><given-names>H</given-names></name>
<name><surname>Ran</surname><given-names>L</given-names></name>
<name><surname>Ye</surname><given-names>J</given-names></name>
<name><surname>Xie</surname><given-names>W</given-names></name>
<name><surname>Lu</surname><given-names>J</given-names></name>
<etal/>
</person-group><year>2024</year><article-title>Dynasore alleviates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome-mediated pyroptosis</article-title><source>Drug Des. Devel. Ther.</source><volume>18</volume><fpage>1369</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S444408</pub-id><!--<pub-id pub-id-type="pmcid">PMC11055558</pub-id>--><pub-id pub-id-type="pmid">38681210</pub-id>
</element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jorgensen</surname><given-names>SCJ</given-names></name>
<name><surname>Rybak</surname><given-names>MJ</given-names></name>
</person-group><year>2018</year><article-title>Meropenem and Vaborbactam: stepping up the battle against Carbapenem-resistant Enterobacteriaceae</article-title><source>Pharmacotherapy</source><volume>38</volume><fpage>444</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/phar.2092</pub-id><pub-id pub-id-type="pmid">29427523</pub-id>
</element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>L</given-names></name>
<name><surname>Pascual</surname><given-names>A</given-names></name>
<name><surname>Hern&#x000e1;ndez-All&#x000e9;s</surname><given-names>S</given-names></name>
<name><surname>Alvarez-D&#x000ed;az</surname><given-names>D</given-names></name>
<name><surname>Su&#x000e1;rez</surname><given-names>AI</given-names></name>
<name><surname>Tran</surname><given-names>J</given-names></name>
<etal/>
</person-group><year>1999</year><article-title>Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>Antimicrob. Agents Chemother.</source><volume>43</volume><fpage>1669</fpage><lpage>1673</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.7.1669</pub-id><!--<pub-id pub-id-type="pmcid">PMC89341</pub-id>--><pub-id pub-id-type="pmid">10390220</pub-id>
</element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lv</surname><given-names>L</given-names></name>
<name><surname>Wan</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>Gao</surname><given-names>X</given-names></name>
<name><surname>Yang</surname><given-names>Q</given-names></name>
<name><surname>Partridge</surname><given-names>SR</given-names></name>
<etal/>
</person-group><year>2020</year><article-title>Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>mBio</source><volume>11</volume><fpage>e02930</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1128/mBio.02930-19</pub-id><!--<pub-id pub-id-type="pmcid">PMC7064769</pub-id>--><pub-id pub-id-type="pmid">32127452</pub-id>
</element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>X</given-names></name>
<name><surname>Huan</surname><given-names>Q</given-names></name>
<name><surname>Huang</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>R</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
<etal/>
</person-group><year>2022</year><article-title>Metformin reverses tmexCD1-toprJ1- and tet(A)-mediated high-level tigecycline resistance in <italic toggle="yes">K. pneumoniae</italic></article-title><source>Antibiotics (Basel, Switzerland)</source><volume>11</volume><fpage>162</fpage><pub-id pub-id-type="doi">10.3390/antibiotics11020162</pub-id><!--<pub-id pub-id-type="pmcid">PMC8868462</pub-id>--><pub-id pub-id-type="pmid">35203765</pub-id>
</element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Zhuang</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>C</given-names></name>
<name><surname>Jia</surname><given-names>H</given-names></name>
<name><surname>He</surname><given-names>F</given-names></name>
<name><surname>Ruan</surname><given-names>Z</given-names></name>
</person-group><year>2024</year><article-title>Global emergence of Gram-negative bacteria carrying the mobilised RND-type efflux pump gene cluster tmexCD-toprJ variants</article-title><source>Lancet Microbe</source><volume>5</volume><elocation-id>e105</elocation-id><pub-id pub-id-type="doi">10.1016/S2666-5247(23)00338-5</pub-id><pub-id pub-id-type="pmid">37972633</pub-id>
</element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lam</surname><given-names>PL</given-names></name>
<name><surname>Wong</surname><given-names>RS</given-names></name>
<name><surname>Lam</surname><given-names>KH</given-names></name>
<name><surname>Hung</surname><given-names>LK</given-names></name>
<name><surname>Wong</surname><given-names>MM</given-names></name>
<name><surname>Yung</surname><given-names>LH</given-names></name>
<etal/>
</person-group><year>2020</year><article-title>The role of reactive oxygen species in the biological activity of antimicrobial agents: an updated mini review</article-title><source>Chem. Biol. Interact.</source><volume>320</volume><elocation-id>109023</elocation-id><pub-id pub-id-type="doi">10.1016/j.cbi.2020.109023</pub-id><pub-id pub-id-type="pmid">32097615</pub-id>
</element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ezraty</surname><given-names>B</given-names></name>
<name><surname>Gennaris</surname><given-names>A</given-names></name>
<name><surname>Barras</surname><given-names>F</given-names></name>
<name><surname>Collet</surname><given-names>JF</given-names></name>
</person-group><year>2017</year><article-title>Oxidative stress, protein damage and repair in bacteria</article-title><source>Nat. Rev. Microbiol.</source><volume>15</volume><fpage>385</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.26</pub-id><pub-id pub-id-type="pmid">28420885</pub-id>
</element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Guo</surname><given-names>H</given-names></name>
<name><surname>Hai</surname><given-names>Y</given-names></name>
<name><surname>Luo</surname><given-names>Y</given-names></name>
<name><surname>Yue</surname><given-names>T</given-names></name>
</person-group><year>2020</year><article-title>Mechanism and intervention measures of iron side effects on the intestine</article-title><source>Crit. Rev. Food Sci. Nutr.</source><volume>60</volume><fpage>2113</fpage><lpage>2125</lpage><pub-id pub-id-type="doi">10.1080/10408398.2019.1630599</pub-id><pub-id pub-id-type="pmid">31232087</pub-id>
</element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vuotto</surname><given-names>C</given-names></name>
<name><surname>Longo</surname><given-names>F</given-names></name>
<name><surname>Pascolini</surname><given-names>C</given-names></name>
<name><surname>Donelli</surname><given-names>G</given-names></name>
<name><surname>Balice</surname><given-names>MP</given-names></name>
<name><surname>Libori</surname><given-names>MF</given-names></name>
<etal/>
</person-group><year>2017</year><article-title>Biofilm formation and antibiotic resistance in <italic toggle="yes">Klebsiella pneumoniae</italic> urinary strains</article-title><source>J. Appl. Microbiol.</source><volume>123</volume><fpage>1003</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1111/jam.13533</pub-id><pub-id pub-id-type="pmid">28731269</pub-id>
</element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahdar</surname><given-names>HA</given-names></name>
<name><surname>Malekabad</surname><given-names>ES</given-names></name>
<name><surname>Dadashi</surname><given-names>AR</given-names></name>
<name><surname>Takei</surname><given-names>E</given-names></name>
<name><surname>Keikha</surname><given-names>M</given-names></name>
<name><surname>Kazemian</surname><given-names>H</given-names></name>
<etal/>
</person-group><year>2019</year><article-title>Correlation between biofilm formation and carbapenem resistance among clinical isolates of <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>Ethiop. J. Health Sci.</source><volume>29</volume><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">31741645</pub-id>
</element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>He</surname><given-names>M</given-names></name>
<name><surname>Kong</surname><given-names>N</given-names></name>
<name><surname>Niu</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>A</given-names></name>
<name><surname>Yan</surname><given-names>Y</given-names></name>
</person-group><year>2024</year><article-title>Study on the inhibition activity and mechanism of Tanreqing against <italic toggle="yes">Klebsiella pneumoniae</italic> biofilm formation in vitro and in vivo</article-title><source>Front. Cell. Infect. Microbiol.</source><volume>14</volume><elocation-id>1368450</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2024.1368450</pub-id><!--<pub-id pub-id-type="pmcid">PMC11024231</pub-id>--><pub-id pub-id-type="pmid">38638833</pub-id>
</element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vestby</surname><given-names>LK</given-names></name>
<name><surname>Gr&#x000f8;nseth</surname><given-names>T</given-names></name>
<name><surname>Simm</surname><given-names>R</given-names></name>
<name><surname>Nesse</surname><given-names>LL</given-names></name>
</person-group><year>2020</year><article-title>Bacterial biofilm and its role in the pathogenesis of disease</article-title><source>Antibiotics (Basel, Switzerland)</source><volume>9</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.3390/antibiotics9020059</pub-id><!--<pub-id pub-id-type="pmcid">PMC7167820</pub-id>--><pub-id pub-id-type="pmid">32028684</pub-id>
</element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L</given-names></name>
<name><surname>Gao</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Ma</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<etal/>
</person-group><year>2024</year><article-title>Relationship between biofilm formation and antibiotic resistance of <italic toggle="yes">Klebsiella pneumoniae</italic> and updates on antibiofilm therapeutic strategies</article-title><source>Front. Cell. Infect. Microbiol.</source><volume>14</volume><elocation-id>1324895</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2024.1324895</pub-id><!--<pub-id pub-id-type="pmcid">PMC10920351</pub-id>--><pub-id pub-id-type="pmid">38465230</pub-id>
</element-citation></ref><ref id="ref26"><label>26</label><mixed-citation publication-type="other">Singh A, Amod A, Pandey P, Bose P, Pingali MS, Shivalkar S, <italic toggle="yes">et al</italic>. 2022. Bacterial biofilm infections, their resistance to antibiotics therapy and current treatment strategies. <italic toggle="yes">Biomed. Mater.</italic>
<bold>17.</bold> doi: 10.1088/1748-605X/ac50f6.
<pub-id pub-id-type="doi">10.1088/1748-605X/ac50f6</pub-id>
<pub-id pub-id-type="pmid">35105823</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>SM</given-names></name>
<name><surname>Cardoso</surname><given-names>MH</given-names></name>
<name><surname>C&#x000e2;ndido Ede</surname><given-names>S</given-names></name>
<name><surname>Franco</surname><given-names>OL</given-names></name>
</person-group><year>2016</year><article-title>Understanding, preventing and eradicating <italic toggle="yes">Klebsiella pneumoniae</italic> biofilms</article-title><source>Future Microbiol.</source><volume>11</volume><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.2217/fmb.16.7</pub-id><pub-id pub-id-type="pmid">27064296</pub-id>
</element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>M</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>X</given-names></name>
<name><surname>Ding</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Shen</surname><given-names>J</given-names></name>
<etal/>
</person-group><year>2020</year><article-title>A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens</article-title><source>Nat. Microbiol.</source><volume>5</volume><fpage>1040</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0723-z</pub-id><pub-id pub-id-type="pmid">32424338</pub-id>
</element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>W</given-names></name>
<name><surname>Chen</surname><given-names>G</given-names></name>
<name><surname>Dou</surname><given-names>K</given-names></name>
<name><surname>Yi</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>D</given-names></name>
<name><surname>Zhou</surname><given-names>Q</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Eugenol eliminates carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> via reactive oxygen species mechanism</article-title><source>Front. Microbiol.</source><volume>14</volume><elocation-id>1090787</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1090787</pub-id><!--<pub-id pub-id-type="pmcid">PMC9978153</pub-id>--><pub-id pub-id-type="pmid">36876091</pub-id>
</element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guan</surname><given-names>X</given-names></name>
<name><surname>Jin</surname><given-names>L</given-names></name>
<name><surname>Yu</surname><given-names>D</given-names></name>
<name><surname>He</surname><given-names>Y</given-names></name>
<name><surname>Bao</surname><given-names>Y</given-names></name>
<name><surname>Zhou</surname><given-names>H</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Glycyrrhetinic acid prevents carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>induced cell injury by inhibiting mitochondrial dysfunction via Nrf-2 pathway</article-title><source>Microb. Pathog.</source><volume>177</volume><elocation-id>105825</elocation-id><pub-id pub-id-type="doi">10.1016/j.micpath.2022.105825</pub-id><pub-id pub-id-type="pmid">36244594</pub-id>
</element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guan</surname><given-names>X</given-names></name>
<name><surname>Jin</surname><given-names>L</given-names></name>
<name><surname>Zhou</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Wan</surname><given-names>H</given-names></name>
<name><surname>Bao</surname><given-names>Y</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Polydatin prevent lung epithelial cell from <italic toggle="yes">Carbapenem-resistant</italic>
<italic toggle="yes">Klebsiella pneumoniae</italic> injury by inhibiting biofilm formation and oxidative stress</article-title><source>Sci. Rep.</source><volume>13</volume><elocation-id>17736</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-44836-7</pub-id><!--<pub-id pub-id-type="pmcid">PMC10584862</pub-id>--><pub-id pub-id-type="pmid">37853059</pub-id>
</element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mattick</surname><given-names>JS</given-names></name>
<name><surname>Amaral</surname><given-names>PP</given-names></name>
<name><surname>Carninci</surname><given-names>P</given-names></name>
<name><surname>Carpenter</surname><given-names>S</given-names></name>
<name><surname>Chang</surname><given-names>HY</given-names></name>
<name><surname>Chen</surname><given-names>LL</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Long non-coding RNAs: definitions, functions, challenges and recommendations</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>24</volume><fpage>430</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00566-8</pub-id><!--<pub-id pub-id-type="pmcid">PMC10213152</pub-id>--><pub-id pub-id-type="pmid">36596869</pub-id>
</element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>C</given-names></name>
<name><surname>Jin</surname><given-names>L</given-names></name>
<name><surname>Zhou</surname><given-names>H</given-names></name>
<name><surname>Yang</surname><given-names>J</given-names></name>
<name><surname>Wan</surname><given-names>H</given-names></name>
</person-group><year>2024</year><article-title>Chlorogenic acid inhibits macrophage PANoptosis induced by cefotaxime-resistant <italic toggle="yes">Escherichia coli</italic></article-title><source>Arch. Microbiol.</source><volume>206</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1007/s00203-023-03777-5</pub-id><pub-id pub-id-type="pmid">38236396</pub-id>
</element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>XQ</given-names></name>
<name><surname>Zhou</surname><given-names>HF</given-names></name>
<name><surname>Lu</surname><given-names>YY</given-names></name>
<name><surname>Chen</surname><given-names>JK</given-names></name>
<name><surname>Wan</surname><given-names>HT</given-names></name>
<name><surname>Zhang</surname><given-names>YY</given-names></name>
</person-group><year>2016</year><article-title>Protective effects of <italic toggle="yes">Yinhuapinggan granule</italic> on mice with influenza viral pneumonia</article-title><source>Int. Immunopharmacol.</source><volume>30</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2015.11.029</pub-id><pub-id pub-id-type="pmid">26655878</pub-id>
</element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>X</given-names></name>
<name><surname>Jin</surname><given-names>L</given-names></name>
<name><surname>Zhou</surname><given-names>H</given-names></name>
<name><surname>Wan</surname><given-names>H</given-names></name>
<name><surname>Wan</surname><given-names>H</given-names></name>
<name><surname>Yang</surname><given-names>J</given-names></name>
</person-group><year>2023</year><article-title>Amygdalin reverses macrophage PANoptosis induced by drug-resistant <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Microbiol. Biotechnol.</source><volume>33</volume><fpage>1281</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.4014/jmb.2306.06030</pub-id><!--<pub-id pub-id-type="pmcid">PMC10619555</pub-id>--><pub-id pub-id-type="pmid">37559205</pub-id>
</element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Tong</surname><given-names>Z</given-names></name>
<name><surname>Shi</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>R</given-names></name>
<name><surname>Upton</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
</person-group><year>2021</year><article-title>Drug repurposing for next-generation combination therapies against multidrugresistant bacteria</article-title><source>Theranostics</source><volume>11</volume><fpage>4910</fpage><lpage>4928</lpage><pub-id pub-id-type="doi">10.7150/thno.56205</pub-id><!--<pub-id pub-id-type="pmcid">PMC7978324</pub-id>--><pub-id pub-id-type="pmid">33754035</pub-id>
</element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tong</surname><given-names>Z</given-names></name>
<name><surname>Xu</surname><given-names>T</given-names></name>
<name><surname>Deng</surname><given-names>T</given-names></name>
<name><surname>Shi</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
</person-group><year>2021</year><article-title>Benzydamine reverses TMexCD-TOprJ-mediated high-level tigecycline resistance in gram-negative bacteria</article-title><source>Pharmaceuticals (Basel, Switzerland)</source><volume>14</volume><fpage>907</fpage><pub-id pub-id-type="doi">10.3390/ph14090907</pub-id><!--<pub-id pub-id-type="pmcid">PMC8470189</pub-id>--><pub-id pub-id-type="pmid">34577607</pub-id>
</element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brynildsen</surname><given-names>MP</given-names></name>
<name><surname>Winkler</surname><given-names>JA</given-names></name>
<name><surname>Spina</surname><given-names>CS</given-names></name>
<name><surname>MacDonald</surname><given-names>IC</given-names></name>
<name><surname>Collins</surname><given-names>JJ</given-names></name>
</person-group><year>2013</year><article-title>Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production</article-title><source>Nat. Biotechnol.</source><volume>31</volume><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/nbt.2458</pub-id><!--<pub-id pub-id-type="pmcid">PMC3568245</pub-id>--><pub-id pub-id-type="pmid">23292609</pub-id>
</element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Hu</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Nie</surname><given-names>T</given-names></name>
<etal/>
</person-group><year>2021</year><article-title>A novel tigecycline adjuvant ML-7 reverses the susceptibility of tigecyclineresistant <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>Front. Cell. Infect. Microbiol.</source><volume>11</volume><elocation-id>809542</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.809542</pub-id><!--<pub-id pub-id-type="pmcid">PMC8766836</pub-id>--><pub-id pub-id-type="pmid">35071055</pub-id>
</element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dharmaraja</surname><given-names>AT</given-names></name>
</person-group><year>2017</year><article-title>Role of Reactive Oxygen Species (ROS) in therapeutics and drug resistance in cancer and bacteria</article-title><source>J. Med. Chem.</source><volume>60</volume><fpage>3221</fpage><lpage>3240</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01243</pub-id><pub-id pub-id-type="pmid">28135088</pub-id>
</element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>SK</given-names></name>
<name><surname>Yusoff</surname><given-names>K</given-names></name>
<name><surname>Thomas</surname><given-names>W</given-names></name>
<name><surname>Akseer</surname><given-names>R</given-names></name>
<name><surname>Alhosani</surname><given-names>MS</given-names></name>
<name><surname>Abushelaibi</surname><given-names>A</given-names></name>
<etal/>
</person-group><year>2020</year><article-title>Lavender essential oil induces oxidative stress which modifies the bacterial membrane permeability of carbapenemase producing <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>Sci. Rep.</source><volume>10</volume><fpage>819</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-55601-0</pub-id><!--<pub-id pub-id-type="pmcid">PMC6972767</pub-id>--><pub-id pub-id-type="pmid">31964900</pub-id>
</element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perez</surname><given-names>AP</given-names></name>
<name><surname>Perez</surname><given-names>N</given-names></name>
<name><surname>Lozano</surname><given-names>CMS</given-names></name>
<name><surname>Altube</surname><given-names>MJ</given-names></name>
<name><surname>de Farias</surname><given-names>MA</given-names></name>
<name><surname>Portugal</surname><given-names>RV</given-names></name>
<etal/>
</person-group><year>2019</year><article-title>The anti MRSA biofilm activity of <italic toggle="yes">Thymus vulgaris</italic> essential oil in nanovesicles</article-title><source>Phytomed. Int. J. Phytother. Phytopharmacol.</source><volume>57</volume><fpage>339</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2018.12.025</pub-id><pub-id pub-id-type="pmid">30826631</pub-id>
</element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Zhao</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>C</given-names></name>
<name><surname>Wu</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
</person-group><year>2023</year><article-title>In-vitro antibacterial activity and mechanism of <italic toggle="yes">Monarda didyma</italic> essential oils against <italic toggle="yes">Carbapenem-resistant</italic>
<italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>BMC Microbiol.</source><volume>23</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.1186/s12866-023-03015-4</pub-id><!--<pub-id pub-id-type="pmcid">PMC10512558</pub-id>--><pub-id pub-id-type="pmid">37730531</pub-id>
</element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>M</given-names></name>
<name><surname>Pei</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Feng</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Gao</surname><given-names>MQ</given-names></name>
</person-group><year>2019</year><article-title>LncRNA XIST mediates bovine mammary epithelial cell inflammatory response via NF-&#x003ba;B/NLRP3 inflammasome pathway</article-title><source>Cell Prolif.</source><volume>52</volume><elocation-id>e12525</elocation-id><pub-id pub-id-type="doi">10.1111/cpr.12525</pub-id><!--<pub-id pub-id-type="pmcid">PMC6430464</pub-id>--><pub-id pub-id-type="pmid">30362186</pub-id>
</element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>SC</given-names></name>
</person-group><year>2017</year><article-title>The non-canonical NF-&#x003ba;B pathway in immunity and inflammation</article-title><source>Nat. Rev. Immunol.</source><volume>17</volume><fpage>545</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.52</pub-id><!--<pub-id pub-id-type="pmcid">PMC5753586</pub-id>--><pub-id pub-id-type="pmid">28580957</pub-id>
</element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>He</surname><given-names>C</given-names></name>
<name><surname>Ma</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<etal/>
</person-group><year>2021</year><article-title>Qingwenzhike prescription alleviates acute lung injury induced by LPS via inhibiting TLR4/NF-kB pathway and NLRP3 inflammasome activation</article-title><source>Front. Pharmacol.</source><volume>12</volume><elocation-id>790072</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.790072</pub-id><!--<pub-id pub-id-type="pmcid">PMC8733650</pub-id>--><pub-id pub-id-type="pmid">35002723</pub-id>
</element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McVey</surname><given-names>MJ</given-names></name>
<name><surname>Steinberg</surname><given-names>BE</given-names></name>
<name><surname>Goldenberg</surname><given-names>NM</given-names></name>
</person-group><year>2021</year><article-title>Inflammasome activation in acute lung injury</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><volume>320</volume><fpage>L165</fpage><lpage>L178</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00303.2020</pub-id><pub-id pub-id-type="pmid">33296269</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Fig. 1</label><caption><title>Biological characterization of bacteria.</title><p>(<bold>A</bold>) Chemical structure of CA. (<bold>B</bold>) Chemical structure of Pue. (<bold>C</bold>) Chemical structure of Amy. (<bold>D</bold>) Chemical structure of PD. (<bold>E</bold>) Time growth curves of CA, Pue, Amy, and PD. (<bold>F</bold>) MIC assay of MER. (G) MIC assay of CTX. (H) MIC determination of TIG.</p></caption><graphic xlink:href="jmb-35-e2412014-f1" position="float"/></fig><fig position="float" id="F2"><label>Fig. 2</label><caption><title>Synergistic activity of combination of OAY-MER against MDR-KP.</title><p>(<bold>A</bold>) Activity assay of OAY dosing (<bold>B</bold>) Activity assay of OAY dosing in combination with MER. (<bold>C-E</bold>) Apoptosis-like results. 1: Com. 1; 2: Com. 1 + MER; 3: Com. 7; 4: Com. 7 + MER; 5: YHPG; 6: YHPG + MER. *<italic toggle="yes">p</italic> &#x0003c; 0.05 vs. Ctrl group, **<italic toggle="yes">p</italic> &#x0003c; 0.01 vs. Ctrl group.</p></caption><graphic xlink:href="jmb-35-e2412014-f2" position="float"/></fig><fig position="float" id="F3"><label>Fig. 3</label><caption><title>OAY/YHPG-MER combination exerted synergy inhibiting the expression of tmexCD1-<italic toggle="yes">toprJ1</italic> and increasing ROS, which damaged the bacterial wall, leading to apoptosis-like.</title><p>(<bold>A</bold>) Relative expression of <italic toggle="yes">tmexC1</italic>, <italic toggle="yes">tmexD1</italic>, and <italic toggle="yes">toprJ1</italic> in the presence of MER (64 &#x003bc;g/ml), OAY, and their combinations. (<bold>B</bold>) ROS. 1: Com. 1; 2: Com. 1 + MER; 3: Com. 7; 4: Com. 7 + MER; 5: YHPG; 6: YHPG + MER. *<italic toggle="yes">p</italic> &#x0003c; 0.05 vs. Ctrl group, **<italic toggle="yes">p</italic> &#x0003c; 0.01 vs. Ctrl group.</p></caption><graphic xlink:href="jmb-35-e2412014-f3" position="float"/></fig><fig position="float" id="F4"><label>Fig. 4</label><caption><title>Effects of OAY/YHPG on MDR-KP biofilm formation.</title><p>Crystal violet staining of MDR-KP biofilms treated with OAY/YHPG -MER combination (<bold>A-B</bold>). (<bold>C</bold>) AKP activity of MDR-KP. (<bold>D, E</bold>) NP activity of MDR-KP. 1: Com. 1; 2: Com. 1 + MER; 3: Com. 7; 4: Com. 7 + MER; 5: YHPG; 6: YHPG + MER. *<italic toggle="yes">p</italic> &#x0003c; 0.05 vs. Ctrl group, **<italic toggle="yes">p</italic> &#x0003c; 0.01 vs. Ctrl group.</p></caption><graphic xlink:href="jmb-35-e2412014-f4" position="float"/></fig><fig position="float" id="F5"><label>Fig. 5</label><caption><title>OAY (Com.7)/YHPG alleviated the pathological characteristics of lung induced in mice by MDR-KP.</title><p>(<bold>A</bold>) The images of lungs in different groups, with HE staining. (<bold>B</bold>) Statistical results of W/D in different groups. (<bold>C</bold>) Lung bacterial content changes after MDR-KP infection. Effects of YHPG and OAY on SOD (<bold>D</bold>), and MDA (<bold>E</bold>) levels in lung tissues after MDR-KP infection. OAY: Com. 7; #<italic toggle="yes">p</italic> &#x0003c; 0.05 vs. Ctrl group, **<italic toggle="yes">p</italic> &#x0003c; 0.01 vs. Model group.</p></caption><graphic xlink:href="jmb-35-e2412014-f5" position="float"/></fig><fig position="float" id="F6"><label>Fig. 6</label><caption><title>OAY (Com.7) and YHPG reduced lung injury in MDR-KP-infected mice by attenuating GSDMD/ NLRP3/NF-&#x003ba;B expression.</title><p>(<bold>A</bold>) Immunohistochemical staining was used to detect the protein expressions of caspase-1. (<bold>B</bold>) Effects of YHPG and OAY on IL-1&#x003b2; production and secretion in mice from MDR-KP-induced pneumonia mice. (<bold>C</bold>) The protein levels of NLRP3, NF-&#x003ba;B-P-p65, and C-GSDMD were detected by western blotting, and the grayscale values of the bands were analyzed using ImageJ software. <sup>#</sup><italic toggle="yes">p</italic> &#x0003c; 0.05 vs. Ctrl group, <sup>##</sup><italic toggle="yes">p</italic> &#x0003c; 0.01 vs. Ctrl group, *<italic toggle="yes">p</italic> &#x0003c; 0.05 vs. Model group, **<italic toggle="yes">p</italic> &#x0003c; 0.01 vs. Model group.</p></caption><graphic xlink:href="jmb-35-e2412014-f6" position="float"/></fig><fig position="float" id="F7"><label>Fig. 7</label><caption><title>A schematic diagram showed that the OAY when combined with MER reversed tmexCD1-topJ1-mediated MER resistance in MDR-KP and inhibited NF-&#x003ba;B pathway and NLRP3 inflammasome activation.</title></caption><graphic xlink:href="jmb-35-e2412014-f7" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Orthogonal combinations of YHPG active ingredients table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Number</th><th valign="middle" align="center" rowspan="1" colspan="1">CA (&#x003bc;g/ml)</th><th valign="middle" align="center" rowspan="1" colspan="1">Pue (&#x003bc;g/ml)</th><th valign="middle" align="center" rowspan="1" colspan="1">Amy (&#x003bc;g/ml)</th><th valign="middle" align="center" rowspan="1" colspan="1">PD (&#x003bc;g/ml)</th></tr></thead><tbody><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.1</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">128</td><td valign="top" align="center" rowspan="1" colspan="1">237</td><td valign="top" align="center" rowspan="1" colspan="1">62</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.2</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">64</td><td valign="top" align="center" rowspan="1" colspan="1">59.25</td><td valign="top" align="center" rowspan="1" colspan="1">31</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.3</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">118.5</td><td valign="top" align="center" rowspan="1" colspan="1">15.5</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.4</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">59.25</td><td valign="top" align="center" rowspan="1" colspan="1">62</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.5</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">128</td><td valign="top" align="center" rowspan="1" colspan="1">118.5</td><td valign="top" align="center" rowspan="1" colspan="1">31</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.6</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">64</td><td valign="top" align="center" rowspan="1" colspan="1">237</td><td valign="top" align="center" rowspan="1" colspan="1">15.5</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.7</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">64</td><td valign="top" align="center" rowspan="1" colspan="1">118.5</td><td valign="top" align="center" rowspan="1" colspan="1">62</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.8</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">237</td><td valign="top" align="center" rowspan="1" colspan="1">31</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Com.9</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">128</td><td valign="top" align="center" rowspan="1" colspan="1">59.25</td><td valign="top" align="center" rowspan="1" colspan="1">15.5</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>The primer sequences for qRT-PCR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Gene</th><th valign="middle" align="center" rowspan="1" colspan="1">Forward (5'-3')</th><th valign="middle" align="center" rowspan="1" colspan="1">Reverse (5'-3')</th></tr></thead><tbody><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">
<italic toggle="yes">tmexC1</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">GTGCGAGCGACCAGC</td><td valign="top" align="center" rowspan="1" colspan="1">TTGAGCCCCTGCGGC</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">
<italic toggle="yes">tmexD1</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">CGTCAACAACGCCAT</td><td valign="top" align="left" rowspan="1" colspan="1">CGCGAGCCGTCCTG</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">
<italic toggle="yes">toprJ1</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">CCGACTACGAAGGCA</td><td valign="top" align="left" rowspan="1" colspan="1">CGCAGGTAGTCGTCC</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">16S rRNA</td><td valign="top" align="left" rowspan="1" colspan="1">TTGACGTTACCCGCAGAAGAA</td><td valign="top" align="left" rowspan="1" colspan="1">GCTTGCACCCTCCGTATTACC</td></tr></tbody></table></table-wrap></floats-group></article>